Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Expected to Earn Q4 2024 Earnings of $0.10 Per Share

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Leerink Partnrs increased their Q4 2024 EPS estimates for Ironwood Pharmaceuticals in a research note issued to investors on Monday, September 30th. Leerink Partnrs analyst F. Khurshid now expects that the biotechnology company will post earnings of $0.10 per share for the quarter, up from their previous forecast of $0.09. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.24 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.05 EPS, FY2025 earnings at $0.17 EPS and FY2026 earnings at $0.45 EPS.

Several other analysts have also weighed in on the stock. Leerink Partners assumed coverage on shares of Ironwood Pharmaceuticals in a research note on Monday, September 9th. They set a “market perform” rating and a $5.00 target price for the company. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Wells Fargo & Company lowered their price target on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, August 9th. Craig Hallum lowered their price target on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Finally, Capital One Financial lowered shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $12.00 to $4.00 in a research report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.17.

Ironwood Pharmaceuticals Price Performance

IRWD stock opened at $4.26 on Tuesday. Ironwood Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $15.70. The firm has a fifty day moving average price of $4.91 and a two-hundred day moving average price of $6.35. The firm has a market cap of $666.81 million, a price-to-earnings ratio of -0.63 and a beta of 0.49.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Ironwood Pharmaceuticals by 21.8% in the first quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock worth $170,031,000 after purchasing an additional 3,487,821 shares during the period. Pacer Advisors Inc. lifted its holdings in Ironwood Pharmaceuticals by 23.6% in the 2nd quarter. Pacer Advisors Inc. now owns 8,907,639 shares of the biotechnology company’s stock valued at $58,078,000 after acquiring an additional 1,701,452 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Ironwood Pharmaceuticals by 20.7% in the 2nd quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock valued at $55,889,000 after acquiring an additional 1,472,097 shares during the last quarter. Armistice Capital LLC lifted its holdings in Ironwood Pharmaceuticals by 44.4% in the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock valued at $50,856,000 after acquiring an additional 2,400,000 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Ironwood Pharmaceuticals by 40.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 4,235,580 shares of the biotechnology company’s stock valued at $36,892,000 after acquiring an additional 1,226,377 shares during the last quarter.

Insider Transactions at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the sale, the insider now owns 284,661 shares of the company’s stock, valued at $1,215,502.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 12.90% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.